Featured Content

Winston Wong, PharmD
AVP, Pharmacy Management CareFirst BlueCross BlueShield

Studies: Some Cancer Treatments Can Be Skipped

(Washington Post/Associated Press) Dec 11, 2013 - Tens of thousands of women each year might be able to skip at least some of the grueling treatments for breast cancer - which can include surgery, heavy chemo and radiation - without greatly harming their odds of survival, new research suggests.

Commentary: Let us not forget that there are genomic tests out there that can predict the risk of recurrence as well, thus...

 1 comments  Add a comment
 facebook share button  twitter share button  linkedin share button



OBR Daily   Our free daily oncology focused e-news service.
Subscribe»  |  Search Archives»

Today's News

Two Experimental Breast-Cancer Drugs Pass Major Milestone in Study

(Wall Street Journal) Dec 13, 2013 - Two experimental breast-cancer drugs passed a major milestone in a closely watched study that is part of a growing effort to revamp clinical trials and hasten the path of new medicines to the market.
read article (paid subscription required) »

Aveo Says Lead Drug Unlikely to Succeed in Colon Cancer Study

(Reuters) Dec 13, 2013 - Aveo Oncology said its lead experimental drug was unlikely to succeed in a mid-stage colon cancer study that was testing if the drug was superior to an approved treatment.
read article »

Budget Deal, With 3-Month 'Doc Fix' Moves To Senate

(Kaiser Health News) Dec 13, 2013 - As the the House approved a budget deal, Republicans included a provision to prevent a scheduled pay cut for doctors who treat Medicare patients. Meanwhile, House and Senate committees approved bills to repeal that Sustainable Growth Rate formula, but prospects for passage are unclear.
read article »

 

View ALL News »




News Story Commentary By Academic and Community Oncologists



Studies: Some Cancer Treatments Can Be Skipped (Washington Post/Associated Press)

Let us not forget that there are genomic tests out there that can predict the risk of recurrence as well, thus...posted by: Winston Wong, PharmD

Game-Changing Shift Occurring in Cancer Discovery and Treatment (ASCO)

There is no doubt that research is making many advances, but as noted at the beginning...at what cost are the advances...posted by: Winston Wong, PharmD

Is It Time To Cap Chemo Rx In Advanced Lung Cancer? (Pharmacy Practice News)

So more is not always better. This is a lesson we learned in the mid- to later 90's that treatment beyond 4-6 cycles...posted by: Thomas Marsland, MD

Unlocking How Brain Cancer Cells Hide from Drugs (UCLA JCCC)

Ahhh. It sounds like the brain tumor cells are out-smarting the "smart drugs". I wonder what it will cost now...posted by: Winston Wong, PharmD

CARING Criteria Shows 1 Year Death Risk at Time of Hospital Admission (UCCC/In the Clinic blog)

While I understand the concepts here of using the tool to match to patient need and decisions, it would be interesting...posted by: Winston Wong, PharmD






OBR Training


Learn more about the OBR training platform, developed to provide an in-depth understanding of the unique business dynamics of today's oncology landscape.






PanPacific_300x250

The most comprehensive and up-to-date oncology pipeline information on the web!
OBR Pipeline Online™






View company profiles, indexes, and streaming stock quotes of over 200 oncology focused companies.

Winners/Losers

Symbol  %Δ
CNDO +22.47%
PVCT +19.38%
CLSN +14.86%
INSY -15.01%
AVEO -9.31%
IMUC -6.82%


    


OBR Radar

View upcoming pivotal oncology events such as PDUFA dates, ODAC dates, and announcement of phase III clinical trial results


Date: December 25, 2013
Company: Bayer HealthCare / Onyx Pharmaceuticals (Amgen)
Product: Nexavar® (sorafenib) tablets

Date: 4Q 2013
Company: Exelixis
Product: Cabozantinib

Date: January 8 and January 9, 2014
Company: GlaxoSmithKline plc
Product: Mekinist® (trametinib) and Tafinlar® (dabrafenib)

See All OBR Radar items»




OBR's Oncology Events Calendar is a compilation of important upcoming conferences and meetings that is updated daily.